Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus
NCT ID: NCT00799942
Last Updated: 2010-07-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
48 participants
INTERVENTIONAL
2009-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety Study of Neramexane to Treat Congenital and Acquired Nystagmus
NCT00661440
Cross-over Comparison of Gabapentin and Memantine as Treatment for Acquired Nystagmus
NCT00928954
Genetic Studies of Strabismus, Nystagmus, and Associated Disorders
NCT04770519
Eye Muscle Surgery to Treat Congenital Nystagmus
NCT00001866
Electrical Stimulation of the Peripheral Vestibular System in Order to Develop a Vestibular Implant
NCT05246553
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Neramexane mesylate
open-label treatment of 36 months Neramexane mesylate up to 75 mg per day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
81 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merz Pharmaceuticals GmbH
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Leicester, Leicester Royal Infirmary, Ophthalmology Group
Leicester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2007-007663-25
Identifier Type: -
Identifier Source: secondary_id
MRZ 92579-0738/1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.